Praktické lekárnictvo 3/2017

Profile of the patient treated with antipsychotic drugs with risk factors for cardiovascular system disorders

Cardiovascular morbidity, mortality in the patients treated with antipsychotic drugs are increasing, probably related to until etiology of schizophrenia and therefore the mechanism of action of antipsychotic drugs on the cardiovascular system. Wide spectrum factors, from gene to the environment, is responsible for development of cardiovascular risk leading to cardiovascular complications, shorten the life expectancy of the patient with schizophrenia (1). A number of experimental studies on the molecular cellular level have shown that the administration of antipsychotics may influence the expression of gene and functions of postsynaptic proteins, depending on the profile of the receptor of each compound (2). The effect of antipsychotics on the protein level leads to the development of metabolic disorders such as insulin resistance, dyslipidemia, hypertension, weight gain, a complex of symptoms called uniformly metabolic syndrome, which is recently closely linked to the treatment of schizophrenia, since atypical antipsychotics show increased incidence of cardiovascular complications, leading to increasing the mortality from cardiovascular causes.

Keywords: schizophrenia, antipsychotics, cardiovascular morbidity